GKOS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Glaukos Corp (GKOS) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows strong growth potential, supported by bullish technical indicators, positive analyst sentiment, hedge fund buying, and a solid financial performance in the latest quarter. While there are no immediate AI or SwingMax trading signals, the long-term growth trajectory and positive catalysts outweigh the minor negative price fluctuations in the short term.
The technical indicators for GKOS are bullish. The MACD is above 0 and positively contracting, indicating upward momentum. The RSI is in the neutral zone at 73.824, not signaling overbought or oversold conditions. Moving averages are aligned bullishly (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at 122.365 and 125.828, with support at 116.759 and 111.153.
Hedge funds are significantly increasing their positions, with buying up 318.02% over the last quarter.
Analysts have consistently raised price targets, with Citi, Wells Fargo, and others setting targets between $127 and $160, maintaining Buy or Overweight ratings.
FDA approval for repeat dosing of iDose provides long-term growth potential in the glaucoma treatment market.
Financials show strong revenue growth of 35.66% YoY and improved gross margins at 77.8%.
The stock experienced minor post-market declines (-1.74%) and a slight pre-market dip (-0.57%), which could indicate short-term volatility.
No recent news or significant insider activity to further support immediate momentum.
In Q4 2025, Glaukos reported a 35.66% YoY revenue increase to $143.1M. Net income improved significantly, up 298.03% YoY, though still negative at -$133.7M. EPS improved by 286.67% YoY to -2.32. Gross margins increased to 77.8%, up 6.78% YoY, indicating improved operational efficiency despite ongoing losses.
Analyst sentiment is highly positive. Recent ratings include Buy or Overweight from Citi, Wells Fargo, BTIG, and Stifel, with price targets ranging from $127 to $160. Analysts highlight strong growth potential from products like iDose and Epioxa, with revenue acceleration expected in 2027 and beyond.
